for oral use Initial U.S. Approval: 2020
Retsevmo (selpercatinib) is a medication used for the treatment of lung and thyroid cancers with a genetic mutation or fusion in the RET gene. It is the first treatment option available for patients with an abnormal RET gene.
Facts about selpercatinib capsules
Disease Indications-Lung Cancer, Thyroid Cancer
Manufacturer-Lilly, Loxo Oncology
Dosage Forms and strengths: • Capsules: 40 mg, 80 mg.
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “selpercatinib capsules” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For selpercatinib capsules
Approved accessible "selpercatinib capsules"
Retevmo (selpercatinib) capsules were initially approved in 2020. In 2022, it was approved for adults with metastatic solid tumors with a RET gene fusion who have progressed while on or following systemic treatment or who have no satisfactory treatment options.
How can 1 go about obtaining selpercatinib capsules?
If selpercatinib capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
RETEVMO (selpercatinib) capsules, for oral use Initial U.S. Approval: 2020
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa